PATENT CLAIM ANALYSIS

Application Number: 15763366
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "518000"]

Abstract:
Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

Claim (Index 92):
The method of any one of  claims 70 - 91 , wherein the compound that inhibits ATR is represented by Formula A-I: or a pharmaceutically acceptable salt thereof, wherein: R 1  is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R 1  is optionally substituted with 1-5 J 1  groups; R 2  is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R 2  is optionally substituted with 1-5 J 2  groups; L is \u2014C(O)NH\u2014 or \u2014C(O)N(C 1-6 alkyl)-; n is 0 or 1; each J 1  and J 2  is independently halo, \u2014CN, \u2014NO 2 , \u2014V 1 \u2014R, or \u2014(V 2 ) m -Q; V 1  is a C 1-10 aliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR\u2033, S, C(O), S(O), or S(O) 2 ; V 1  is optionally substituted with 1-6 occurrences of J V1 ; V 2  is a C 1-10 aliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR\u2033, S, C(O), S(O), or S(O) 2 ; V 2  is optionally substituted with 1-6 occurrences of J V2 ; m is 0 or 1; Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 9-10 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 J Q ; each J V1  or J V2  is independently halogen, CN, NH 2 , NO 2 , C 1-4 aliphatic, NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , OH, O(C 1-4 aliphatic), CO 2 H, CO 2 (C 1-4 aliphatic), C(O)NH 2 , C(O)NH(C 1-4 aliphatic), C(O)N(C 1-4 aliphatic) 2 , NHCO(C 1-4 aliphatic), N(C 1-4 aliphatic)CO(C 1-4 aliphatic), SO 2 (C 1-4 aliphatic), NHSO 2 (C 1-4 aliphatic), or N(C 1-4 aliphatic)SO 2 (C 1-4 aliphatic), wherein said C 1-4 aliphatic is optionally substituted with halo; R is H or C 1-6 aliphatic wherein said C 1-6 aliphatic is optionally substituted with 1-4 occurrences of NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), CO(C 1-4 aliphatic), O(haloC 1-4 aliphatic), or haloC 1-4 aliphatic; each J Q  is independently halo, oxo, CN, NO 2 , X\u2014R, or \u2014(X) p -Q 4 ; p is 0 or 1; X is C 1-10 aliphatic; wherein 1-3 methylene units of said C 1-6 aliphatic are optionally replaced with \u2014NR, \u2014O\u2014, \u2014S\u2014, C(O), S(O) 2 , or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO(C 1-4 aliphatic), CO 2 H, CO 2 (C 1-4 aliphatic), C(O)NH 2 , C(O)NH(C 1-4 aliphatic), C(O)N(C 1-4 aliphatic) 2 , SO(C 1-4 aliphatic), SO 2 (C 1-4 aliphatic), SO 2 NH(C 1-4 aliphatic), SO 2 N(C 1-4 aliphatic) 2 , NHC(O)(C 1-4 aliphatic), N(C 1-4 aliphatic)C(O)(C 1-4 aliphatic), wherein said C 1-4 aliphatic is optionally substituted with 1-3 occurrences of halo; Q 4  is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 8-10 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q 4  is optionally substituted with 1-5 J Q4 ; J Q4  is halo, CN, or C 1-4 alkyl wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O) 2 ; R is H or C 1-4 alkyl wherein said C 1-4 alkyl is optionally substituted with 1-4 halo; R\u2033 and R* are each independently H, C 1-4 alkyl, or is absent; wherein said C 1-4 alkyl is optionally substituted with 1-4 halo.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 90.0
- Lexical Diversity: 1.71429
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15031426', '15665506', '12988755', '14596052', '15081076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8082499538482246
- 35 USC 102 Novelty (BERT): 0.5203008441465464
- Combined Prediction Score: 0.7794550428780568
- Mean Citation Score: 311.3153240000001
- Max Citation Score: 332.41208
- Similarity Product: 262.90082800151833

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test